# Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke

> **NCT01849887** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of California, Irvine**

## Conditions studied

- Ischemic Stroke

## Interventions

- **BIOLOGICAL:** bone marrow-derived mesenchymal stem cells
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01849887
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never started
- **Last updated:** 2016-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849887, "Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01849887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*